Company Overview and News

0
MGIC Investment (MTG) Q2 Earnings Beat on Lower Loss & Tax

2018-07-19 zacks
MGIC Investment Corporation (MTG - Free Report) reported second-quarter 2018 operating net income per share of 49 cents, surpassing the Zacks Consensus Estimate by 36.1%. The bottom line also soared 58.1% year over year on higher revenues, lower loss and reduction in tax.
FNFV PGR MTG RLI FNF

0
RLI Earnings Beat Estimates, Revenues Improve Y/Y in Q2

2018-07-19 zacks
RLI Corp.’s (RLI - Free Report) second-quarter 2018 operating earnings of 60 cents per share beat the Zacks Consensus Estimate by 9.1%. However, the bottom line slipped 1.6% year over year.
ABI FNFV PGR MTG RLI FNF

2
Fidelity National Financial Inc (FNF) CEO Randy Quirk on Q2 2018 Results - Earnings Call Transcript

2018-07-18 seekingalpha
Fidelity National Financial Inc (NYSE:FNF) Q2 2018 Earnings Conference Call July 18, 2018 11:30 AM ET
STC FNFV FNF

16
Fidelity National (FNF) Q2 Earnings Top, Title Business Solid

2018-07-18 zacks
Fidelity National Financial, Inc.’s (FNF - Free Report) second-quarter 2018 adjusted earnings from continuing operations of 86 cents per share beat the Zacks Consensus Estimate by 3.6%. The bottom line also improved 34.4% year over year.
GEC GE FNFV RE PGR FAF GNE FNF

0
FNF / Fidelity National Financial, Inc. S-4/A

2018-07-12 sec.gov
Use these links to rapidly review the document Table of Contents INDEX TO FNF'S FINANCIAL STATEMENTS TABLE OF CONTENTS
FNF

115
Oakmark Equity And Income Fund: Second Quarter 2018

2018-07-11 seekingalpha
The Equity and Income Fund earned 0.2% in the quarter, while the Lipper Balanced Fund Index, the Fund’s performance benchmark, gained 1.1%.
PM C.WSA DOV.WI NOV TEL CVS FNF BAC C.WS.B CHTR APY.WI GM.WS.A FNFV C.WS.A GM.WS.B GM.WS.C C.PRP DOV C.PRU GM ORCL C.PRS LBRDB BAC C C.PRL AAL C.PRJ C.PRK BHGE COMM MA ARNC C.PRG TWC LBRDK C.PRC BHI C.PRPCL CGBBW OCLCF JLL LBRDA FL APY GM.WSB UNH

53
Market Climbs Mean Digging Deeper For Ideas

2018-06-08 seekingalpha
A cyclical bottom (maybe?), a special situation, and a consolidating industry leader mark the long side.
LSXMB ZDGE BATRK FWONB LSXMA GNE.PRA PANW BATRR RTTR FNF GNE FWONA DRQ BILI MAT STC FNFV RFL FWONK FAF BATRB LSXMK RFL.WI BATRA

7
Fidelity National Financial: An Analysis Of End Markets

2018-06-05 seekingalpha
Fidelity National Financial (FNF) is the largest title insurer in the United States. There are several reasons why I think title insurers are a great way to participate in home price appreciation over the next decade. First, banks require title insurance for mortgage transactions, so customers are essentially captive. Second, due to price regulations and a consolidated industry, there is very little price competition.
STC TRV FNFV MET FAF BKI FNF

0
FNF / Fidelity National Financial, Inc. DEFA14A

2018-05-31 sec.gov
*** Exercise Your Right to Vote *** Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to Be Held on June 13, 2018 FIDELITY NATIONAL FINANCIAL, INC. You are receiving this communication because you hold shares in
FNF

1
FNF / Fidelity National Financial, Inc. S-4

2018-05-30 sec.gov
Use these links to rapidly review the document Table of Contents INDEX TO FNF'S FINANCIAL STATEMENTS TABLE OF CONTENTS
FNF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to FNF / Fidelity National Financial, Inc. on message board site Silicon Investor.

Fidelity National Financial, Inc. - FNF BBY WMT FNF STC AVEI UEIC CMED FRX KSU Articles from Net
CUSIP: 31620R303